JUNAID SYED: Open Payments
NPI 1942381579 · SAINT LOUIS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$969 in 43 payments from 9 companies in 2025. Trend: 2023 $3,943 · 2024 $1,038 · 2025 $969
Food & beverage: $930Education: $39
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $245 |
| Otsuka America Pharmaceutical, Inc. | 6 | $211 |
| Teva Pharmaceuticals USA, Inc. | 11 | $193 |
| Alkermes, Inc. | 5 | $99 |
| Lundbeck LLC | 3 | $89 |
| Vanda Pharmaceuticals Inc. | 2 | $52 |
| ACADIA Pharmaceuticals Inc | 2 | $43 |
| Janssen Pharmaceuticals, Inc | 1 | $19 |
| E.R. Squibb & Sons, L.L.C. | 1 | $16 |
Products named: CAPLYTA, REXULTI, UZEDY, ARISTADA, AUSTEDO XR, FANAPT, ABILIFY MAINTENA, NUPLAZID.
Industry payments across MO — which companies pay providers there.
